NYSE:LLY

Eli Lilly Stock Insider Trading

Healthcare > Drug Manufacturers - General

Buy LLY

*Your capital is at risk

$1,083.23

+18.39 (+1.73%)

At Close: Jun 03, 2026

Eli Lilly Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -72.92. In total, the insiders bought 24.59M and sold 316.01M LLY shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-72.92
● Buy	24.59M shares
● Sell	316.01M shares
61% Buy Activity Moderate Negative Correlation
Sell Signal High Confidence Nov 14, 2025 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -72.92. Partially supported by a negative historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jan 20, 2026 Buy	Common Stock A-Award	Sulzberger Gabrielle Director	Director	5 Value: $5K
Jan 20, 2026 Buy	Common Stock A-Award	Fyrwald J Erik Director	Director	10 Value: $10K
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	1 322 Value: $1.45M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	1 224 Value: $1.34M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	3 575 Value: $3.90M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	930 Value: $1.01M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	1 070 Value: $1.16M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	7 684 Value: $8.35M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	895 Value: $971.2K
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	24 362 Value: $26.9M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	34 434 Value: $38.0M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	14 937 Value: $16.4M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	20 447 Value: $22.5M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	3 464 Value: $3.85M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	8 513 Value: $9.44M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	6 408 Value: $7.03M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	9 573 Value: $10.5M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	20 668 Value: $22.8M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	40 956 Value: $45.2M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	21 042 Value: $23.2M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	13 701 Value: $15.2M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	16 650 Value: $18.4M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	13 247 Value: $14.7M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	1 072 Value: $1.17M
Jan 07, 2026 Sell	Common Stock S-Sale	Lilly Endowment Inc 10 Percent Owner	10% Owner	420 Value: $459.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ELI LILLY AND COMPANY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer ...

Read Full Profile Here